Answers are grounded in this paper and cite their sources.
Background Chimeric antigen receptor (CAR) T cell therapy has significantly improved outcomes in hematologic malignancies. However, its translation to solid tumors is hampered by on-target, off-tumor toxicity (OTOT) and antigen escape. These obstacles underscore the need for novel strategies that enhance antitumor efficacy while limiting OTOT. Methods We designed a NOT logic-gated CAR natural killer (NK) cell architecture that targets B7H3, a tumor-associated antigen, and endomucin (EMCN), an antigen serving as a safety marker in normal tissues. These dual CAR NK cells selectively targeted and eliminated B7H3-high tumor cells, whereas their activation was suppressed upon encountering normal cell models co-expressing B7H3 and EMCN. A panel of inhibitory intracellular domains derived from T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT), killer cell immunoglobulin-like receptors 2DL1 (KIR2DL1) and 3DL1 (KIR3DL1), and sialic acid-binding immunoglobulin-like lectins 7 and 9 (Siglec-7/9) was screened to identify the optimal module for the EMCN-specific CAR NK cells. Results The dual CAR NK cells demonstrated precise tumor selectivity and markedly reduced OTOT relative to conventional B7H3-targeted CAR NK cells. The KIR3DL1 intracellular domain proved to be the most effective, robustly suppressing cytotoxicity upon recognition of EMCN on B7H3 + engineered SKOV3-EMCN cells and thereby conferring potent protection. Conclusion This KIR3DL1-based inhibitory dual CAR NK cell strategy, which exploits endogenous NK inhibitory signaling, enhances safety and presents a promising advance in CAR-based immunotherapy for solid tumors. Future studies should focus on optimizing this platform and evaluating its clinical potential.
No takes yet. Share an insight, caveat, or question.
唐文静 et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: